

1 **Cystic Fibrosis Transmembrane Conductance Regulator Reduces**

2 **Microtubule-Dependent *Campylobacter jejuni* Invasion**

3

4 Junko Kido¹, Takaaki Shimohata¹, Sachie Amano¹, Sho Hatayama¹, Nguyen

5 Quoc Anh¹, Yuri Sato¹, Yuna Kanda¹, Aya Tentaku¹, Shiho Fukushima¹, Mutsumi

6 Nakahashi², Takashi Uebanso¹, Kazuaki Mawatari¹, Akira Takahashi¹

7 ¹Department of Preventive Environment and Nutrition, Institute of Biomedical

8 Sciences, Tokushima University

9 ²Graduate School of Technology, Industrial and Social Sciences, Tokushima

10 University

11

12 *All correspondence should be addressed to: Takaaki Shimohata, Ph.D.

13 Department of Preventive Environment and Nutrition, Institute of Biomedical

14 Sciences, Tokushima University

15 Tel: +81-88-633-9598, Fax: +81-88-633-7092

16 E-mail: shimohata@tokushima-u.ac.jp

17

18 Running title: Role of CFTR in *Campylobacter jejuni* infection

19

20 **Abstract**

21 *Campylobacter jejuni* (*C. jejuni*) is gastroenteritis inducible food-born pathogen.
22 Invasion and adhesion process are essential for leading gastroenteritis in *C.*
23 *jejuni* infection process. As against bacterial strategy for efficacy invasion and
24 adhesion, mucosal layer play a key role in defense systems, which modulated by
25 several ion channels and transporters mediated water flux on the intestine.
26 Cystic fibrosis transmembrane conductance regulator (CFTR) play the main role
27 in waterflux in intestine, and it closely related with bacterial clearance. We
28 previously reported that *C. jejuni* infection suppresses CFTR channel activity in
29 intestinal epithelial cells, however the mechanism and importance of this
30 suppression is unclear. This study seeks to elucidate the role of CFTR in *C.*
31 *jejuni*-infection. Using HEK293 cells that stably express wild type and mutated
32 CFTR, we found that CFTR attenuated *C. jejuni* invasion, it was not involved
33 bacterial adhesion or intracellular survival but associated with
34 microtubule-dependent cellular transport. Moreover we revealed that CFTR
35 attenuated function of microtubule motor protein but not microtubule stability,
36 which causes inhibition of *C. jejuni*-invasion. Meanwhile, the CFTR mutant

37 G551D-CFTR, which has defects in channel activity, suppressed *C.*
38 *jejuni*-invasion, whereas Δ F508-CFTR, which has defects in maturation, did not
39 suppress, suggesting that CFTR suppression of *C. jejuni*-invasion is related to
40 CFTR maturation but not channel activity.

41 Taken together, mature CFTR inhibited *C. jejuni* invasion by regulating
42 microtubule-mediated pathways. We suggest that CFTR plays a critical role in
43 cellular defenses against *C. jejuni*-invasion, and CFTR suppression may be an
44 initial step in promoting cellular invasion during *C. jejuni*-infection.

45

46

47 **Introduction**

48 *Campylobacter jejuni* (*C. jejuni*) is a spiral-shaped Gram-negative bacterium
49 that is commonly found in the gut microflora of birds or domestic animals used
50 for food. *C. jejuni* is the most common cause of bacterial food-borne illness
51 worldwide and causes gastrointestinal symptoms such as diarrhea, fever,
52 abdominal cramping, and gastroenteritis. Despite its frequency, the virulence
53 factors that contribute to *C. jejuni*-induced gastroenteritis remain largely
54 unknown. Genomic studies revealed that *C. jejuni* strains lack type III secretion
55 systems that are essential for the virulence of many other Gram-negative enteric
56 pathogens (1). Thus, *C. jejuni* pathogenesis likely involves multifactorial
57 virulence processes, including motility, adherence, invasion, and intracellular
58 survival (2,3). Indeed, a study that examined mutant *C. jejuni* strains that were
59 defective in adhesion or invasion found that cultured cells infected with these
60 strains had decreased secretion of the pro-inflammatory cytokine IL-8 (4,5),
61 which suggests that adhesion and invasion are the main pathogenic processes
62 in *C. jejuni* infection (6,7,8,9).

63 In the human gut, the mucosal layer represents the first defense against
64 bacterial adhesion and invasion (10). The binding of intestinal bacteria to host
65 epithelial cells is assumed to play a fundamental role in intestinal bacterial
66 colonization and disease progression (11). A previous study reported that mutant
67 mice with defective mucosal function had a high colonization rate in *C.*
68 *jejuni*-inoculation models (12). The mucosal layer consists of mucins, which are
69 high molecular mass oligomeric glycoproteins. This layer is also critical for
70 maintaining gut homeostasis by regulating water flux through the activity of
71 several ion transporters and ion channels in the intestine (13). Among these ion
72 channels, the cystic fibrosis transmembrane conductance regulator (CFTR), a
73 cAMP-activated chloride channel, is one of the most important factors that
74 governs water movement. CFTR is expressed in several tissues such as those
75 in the lung, pancreas, liver, intestine, sweat ducts, and reproductive system
76 (14,15). In the intestinal tract, CFTR is associated with intestinal tract hydration
77 and clearance of intestinal contents, including bacteria (16).

78 CFTR activation can disrupt the water balance in the gut to lead to diarrhea that

79 is associated with intestinal infections caused by pathogens such as *Escherichia*
80 *coli* (17) and *Vibrio cholera* (18) as well as other infectious bacteria (19).
81 However, we previously reported that *C. jejuni* infection suppressed
82 CFTR-mediated Cl⁻ secretion in intestinal cells (20), which is in opposition to
83 clinical *C. jejuni* symptoms such as diarrhea. Thus, the relationship between
84 CFTR suppression and *C. jejuni* infection is unclear.

85 In order to investigate the relationship between CFTR suppression and *C. jejuni*
86 infection, we referred to respiratory infections that occur in the presence of
87 CFTR mutations that are also associated with cystic fibrosis (CF) (21). CF
88 patients frequently experience respiratory bacterial infection caused by
89 *Pseudomonas aeruginosa* (*P. aeruginosa*) or *Burkholderia cenocepacia* (22).
90 CFTR dysfunction disrupts CFTR-mediated water flux that in turn affects
91 mucosal layer function and attenuates bacterial clearance such that bacteria
92 accumulate in the respiratory tract. Epithelial cells in CF patients have increased
93 cell surface expression of Toll-like receptors (TLR5 and TLR2), contribution of
94 TLR2 has been questioned, and enhanced inflammatory responses (23).

95 Moreover, *P. aeruginosa* is reported to suppress CFTR channel activity by
96 secreting proteins that promote severe inflammation (24,25). These reports
97 indicated that CFTR plays a defensive role against respiratory infection, and
98 dysfunctional CFTR may promote conditions that increase the likelihood of
99 bacterial infection.

100 In this study, we studied the role of CFTR in *C. jejuni* infection. Our data
101 showed that CFTR expression decreased *C. jejuni* invasion. In particular, CFTR
102 expression inhibited microtubule-mediated transport processes during *C. jejuni*
103 invasion, suggesting that CFTR might be a protective factor against *C. jejuni*
104 infection.

105

106 **Material and Methods**

107 ***Bacterial strains and culture conditions.*** The *Campylobacter jejuni* strains
108 NCTC11168 (ATCC 700819) and 81-176 (ATCC BAA2151) were purchased
109 from American Type Culture Collection (ATCC). Bacteria were grown in Muller
110 Hinton (MH) broth (DIFCO 275730) at 37 °C under microaerobic conditions (5%
111 O₂, 10% CO₂ and 85% N₂) for 36 hours. Bacteria were then collected by
112 centrifugation of the media at 12,000 rpm for 3 minutes, concentrated, and
113 grown on selective supplemental media containing *Campylobacter* charcoal
114 differential agar (CCDA:OXOID) for 36 hours. Single colonies were picked and
115 grown in MH broth for 48 hours, after which the media was centrifuged at 12,000
116 rpm 3 minutes, diluted into 15% glycerol (Wako) and stored at -80 °C.

117 For the experiments, samples from frozen bacterial strains were grown in MH
118 broth for 48 hours under microaerobic conditions. After centrifugation at 12,000
119 rpm for 3 min, the supernatant was removed and the pellet was diluted into fresh
120 MH broth and cultured for 36 hours. Bacteria were collected by centrifuging the
121 media at 3,000 rpm for 15 minutes, and the supernatant was removed. The

122 bacterial cells were washed with phosphate buffered saline (PBS(-): 137 mM
123 NaCl, 8.1 mM anhydrous Na₂HPO₄, 2.68 mM KCl, 1.47 mM KH₂PO₄),
124 centrifuged and resuspended in PBS(-). Finally, bacterial cell numbers were
125 adjusted to an optical density of 600 nm for OD₆₀₀=1.0.

126 **Reagents and antibodies.** Forskolin and VX-809 were purchased from
127 Calbiochem and AdooQ Bioscience, respectively. Methyl- β -cyclodextrin (m β -cd),
128 chlorpromazine hydrochloride, paclitaxel and nocodazole were purchased from
129 Sigma-Aldrich. The following antibodies were diluted in 3% skim milk and used
130 for western blotting: CFTR (1:1,000, Millipore), α -tubulin (1:2,000, Wako), and
131 β -actin (1:2,000, Santa Cruz).

132 **Cell culture.** Human embryonic kidney cells (HEK293) were cultured for 3-4
133 days in Dulbecco' s modified eagle' s medium (DMEM) high glucose (Sigma)
134 supplemented with 10% FBS (Thermo-Fisher), and 50 μ g/ml gentamicin (Sigma)
135 at 37°C and 5% CO₂. The human intestinal epithelial cell line T-84 was cultured
136 for 7 days in Ham' s F-12 media (DMEM/F-12, 1:1, Sigma) supplemented with
137 10% FBS (Thermo), and 50 μ g/ml gentamicin (Sigma) at 37 °C and 5% CO₂.

138 The culture medium was changed every 2 days.

139 ***Stable transfection of HEK293 cells.*** HEK293 cells were seeded at a density
140 of 5×10^5 cells/35 mm dish and incubated for 24 hours. Media was changed to
141 DMEM high glucose without FBS and 1 ml Gentamicin High Glucose free. HG
142 free (200 μ l) was mixed with 1 μ g/well pcDNA-wt-CFTR vector and 4 μ g/well
143 Lipofectamine 2000 (Invitrogen) for 15 minutes before incubating at 37°C for 3
144 hours. The cells were then incubated overnight at 37°C in DMEM high glucose
145 containing 20% FBS and 50 μ g/ml gentamicin (1.2 ml total). The supernatant
146 was removed, and the cells were washed with 1 ml 0.02% EDTA/ PBS (-) and
147 then 1 ml 0.02% EDTA/PBS (-) was added and the cells were incubated at 37°C
148 for 5 minutes. The cells were collected by centrifugation at 800 rpm for 3 minutes,
149 and incubated with DMEM high glucose supplemented with 1 mg/ml G418, 10%
150 FBS, and gentamicin for 10 days to produce cells that stably express CFTR.
151 Colonies were picked with paper filter, incubated in a 24-well plate for 2 days
152 before the filter was removed and the cells were grown to confluence. CFTR
153 protein expression was assessed by western blotting and cells with high

154 expression levels were selected. Cells stably expressing mutated CFTR were
155 produced using the same method.

156 **Western blotting.** Cultured cells were washed with PBS (-), diluted into RIPA
157 buffer (pH 7.4, 50 mM Tris-HCl, 150 mM NaCl, 1 mM EDTA, 1% sodium
158 deoxycholate, 0.1% SDS, 1% Triton-X) + 10% protease inhibitor mixture
159 (Nacalai Tesque), centrifuged at 15,000 rpm for 10 min at 4°C, and the
160 supernatant was collected. Protein levels were determined using a BCA Protein
161 assay kit (Thermo). Samples were added to 5× sample buffer (pH 6.8, 250 mM
162 Tris-HCl, 5% SDS, 25% 2-mercaptoethanol, 50% glycerol, BPB) and separated
163 on a SDS-polyacrylamide gel (7.5% or 10%). Proteins were transferred to
164 Immobilon-P Transfer Membranes (Millipore) that were blocked with Tris
165 Buffered Saline with Tween-20 (TBS-T: pH 7.6, 20 mM Tris, 150 mM NaCl,
166 0.02% Polyoxyethylene (20) sorbitan monolaurate) containing 3% skim milk for 1
167 hour at RT and incubated overnight at 4 °C with primary antibodies in TBS-T
168 containing 3% skim milk. After washing with TBS-T for 30 minutes, membranes
169 were exposed to horseradish peroxidase-conjugated secondary antibodies

170 (1:2,000, anti mouse Ig HRP, Biosource) for 2 hours at RT. Membranes were
171 then washed with TBS-T for 30 minutes and detected with ECL (GE Healthcare).
172 Hyperfilm ECL (GE Healthcare) and imaging with a Fuji medical film processor
173 FPM 100 was used to detect CFTR expression. β -actin protein was detected
174 used medical X-ray film or LASS-2000.

175 ***Efflux assay.*** Cells were seeded at a density of 5×10^5 cells/well in a 6-well plate
176 and incubated for 4 days. The supernatants were removed, exchanged for
177 HEPES buffer (10 mM HEPES, 145 mM NaCl, 10 mM glucose, 5 mM KCl, 1 mM
178 $MgCl_2$, 1 mM $CaCl_2$) containing $^{125}I^-$ (2 $\mu Ci/ml$) and incubated at 37 °C for 1
179 hour. The media was removed and the cells were washed twice with isotope-free
180 HEPES buffer before exchanging either for HEPES buffer or HEPES buffer
181 containing 10 μM forskolin. After 5 minutes, supernatants were recovered for
182 sample detection. Cells were incubated 0.1 M NaOH at 37 °C for 1 hour and
183 samples were collected to detect intracellular $^{125}I^-$ using a gamma-counter. The
184 total amount of $^{125}I^-$ in the supernatant and cells was calculated as: % Efflux =
185 $(^{125}I^- \text{ secretion amount} / (^{125}I^- \text{ cellular amount} + ^{125}I^- \text{ secretion amount})) \times 100$

186 ***Transient transfection with shRNA.*** HEK-wt-CFTR or HEK-G551D-CFTR cells
187 were seeded at a density of 1×10^6 cells/well in 6-well plates. Cells were then
188 washed and the media was replaced with HG free before transfection with 1 μ g
189 pLKO-CFTR vector or pLKO.1-puro Non-Target shRNA Control vector using
190 Lipofectamine 2000 reagent (Invitrogen) for 3 hours. DMEM-HG(+) containing
191 20 % FBS and 50 μ g/ml gentamicin was then added to the cells.

192 T84 cells were cultured for 7 days and the cells were harvested with 0.05%
193 trypsin-EDTA and diluted in HEPES buffer. pLKO-CFTR vector or pLKO.1-puro
194 Non-Target shRNA Control vector (2.5-5ug) were mixed with T-84 cells
195 suspension cultures (4×10^5 / 24well) for 20 minutes. Cells were electroporated
196 with 50 voltage-20 ms for 3 times. After electroporation, cells were suspended
197 culture medium for 48 hours.

198 ***Invasion and adhesion and degradation assay.*** For an invasion assay,
199 HEK293 cells and HEK-wt-CFTR cells were seeded at a density of 4×10^5
200 cells/well in 6-well plates and incubated at 37 °C for 4 days. The supernatants
201 were removed and replaced with HG-free media before the cells were infected

202 with *C. jejuni* at a multiplicity of infection (MOI) of 50 for 6 hours at 37 °C in 5%
203 CO₂. After infection, the supernatant was replaced with DMEM-HG(+) containing
204 100 µg/ml gentamicin for 2 hours. The supernatant was removed and the cells
205 were washed with PBS (-) and lysed with PBS containing 1% Triton-X. The
206 lysates were plated on MH agar plates and incubated for 48 hours under
207 microaerobic conditions. HEK-ΔF508-CFTR cells were treated with VX-809 or
208 DMSO at 27 °C for 24 hours before infection.

209 For adhesion assays, HEK293 cells and HEK-wt-CFTR cells were seeded at a
210 density of 1×10⁶ cells/well in 60 mm well plates. After infection, the supernatants
211 were removed and the cells were washed with PBS (-) three times before lysing
212 at 37°C for 5 minutes in PBS (-) containing 0.01% Triton-X. Cell lysates were
213 plated on MH agar plates and incubated for 48 hours under microaerobic
214 conditions.

215 In degradation assays, HEK293 cells and HEK-wt-CFTR cells were seeded at a
216 density of 4×10⁵ cells/well in 6-well plates. After infection, the supernatants were
217 removed and replaced with DMEM-HG(+) containing 100 µg/ml gentamicin for 2,

218 4, 6, or 8 hours. The cells were then lysed with PBS (-) containing 1% Triton-X,
219 plated on MH agar plates, and incubated for 48 hours under microaerobic
220 conditions. All intracellular bacterial number normalized with 1×10^7 cell.

221 ***Separation of soluble and insoluble tubulin.*** HEK293 cells and
222 HEK-wt-CFTR cells were seeded at a density of 4×10^5 cells/well in 6-well plates.
223 The supernatant was removed and the cells were washed with PBS (-) before
224 adding microtubule buffer (0.1 M PIPES pH 7.6, 2 M glycerol, 5 mM MgCl₂, 2
225 mM EGTA) containing 0.1% Triton-X, 1 mM PMSF, 5 µg/ml aprotinin and
226 leupeptin and incubating for 10 min RT. Cells were collected and centrifuged for
227 10 min at 300 g at room temperature. The resulting supernatant represented the
228 soluble fraction. Meanwhile, pellets containing the insoluble fraction were
229 washed again with microtubule buffer and treated with lysis buffer (25 mM
230 Na₂HPO₄ pH 7.2, 400 mM NaCl, 0.5% SDS), and centrifuged for 10 min at
231 20,000 g. Protein concentrations were measured with a BCA protein assay kit
232 and equal amounts of protein were separated by SDS-PAGE. Anti-α-tubulin and
233 anti-β-actin antibodies were used for western blotting.

234 ***RNA isolation and RT-PCR***

235 Total RNA was extracted from T-84 cells using RNeasy Mini Kit (QIAGEN
236 74104) according to the manufacture's instruction. Reverse transcription were
237 preformed with 1 µg of total RNA using the PrimeScript RT-Reagent Kit
238 (TaKaRa RR037A). Quantitative real-time reverse-transcription PCR was
239 performed in the LightCycler Real Time PCR System (Roche Applied Science)
240 with SYBER Premix ExTaq (TaKaRa RR820). 18S ribosomal RNA
241 housekeeping gene (as internal control) and CFTR primers are as follow:

242 forward: 5'-AAACGGCTACCACATCCAAG-3' and reverse:

243 5'-GGCCTCGAAAGAGTCCTGTA-3', forward:

244 5'GCAGTTGATGTGCTTGGCTAG-3' and reverse:

245 GAATCGTACTGCCGCACTTTG-3', respectively. Fold change was calculated

246 relatively to 18S.

247 ***Statistical Analysis***

248 All data were performed statistical analysis by using Student's t-test for paired
249 data. Data were done 3 independent experiments. All tests were one-tailed;

250 *p<0.05; ** p<0.01, NS.: not significant.

251 **Results**

252 **Exogenous CFTR expressed cells were useful for the analyzing of CFTR**
253 **effect on *C. jejuni* infection**

254 In our previous study, CFTR channel activity was suppressed by *C. jejuni*
255 infection (Figure 1A) in T-84 cells, endogenous CFTR expressing cells. To
256 examine whether *C. jejuni* infection affect exogenous CFTR, we established
257 CFTR-expressing HEK293 (HEK-wt-CFTR cells). CFTR expression and channel
258 activity were confirmed by western blot (supplementary Figure 1A) and efflux
259 assay (supplementary Figure 1B), respectively. Interestingly, in contrast to the
260 T-84 cells, CFTR ion channel activity was not suppressed by *C. jejuni* infection in
261 HEK-wt-CFTR cells (Figure 1B). Together, these results suggest that *C. jejuni*
262 infection did not directly affect CFTR function. Thus, we used HEK-wt-CFTR
263 cells, in this study, to assess the CFTR contribution on the *C. jejuni*-infection.

264

265 **Numbers of intracellular *C. jejuni* bacteria were decreased by CFTR**
266 **expression**

267 Adhesion and invasion processes are thought to be essential for *C. jejuni*

268 virulence and infection (26) and decreased amounts of CFTR expression
269 induced by *C. jejuni* may provide increased opportunities for bacterial adhesion
270 or invasion. To test whether CFTR expression levels were related to *C. jejuni*
271 invasion, we investigated the numbers of intracellular bacteria in
272 CFTR-expressing cells infected with *C. jejuni*. Relative to HEK293 cells,
273 HEK-wt-CFTR cells infected by *C. jejuni* for 6 hours showed reduced amounts of
274 *C. jejuni* invasion (Figure 1C). Next, HEK-wt-CFTR cells were transfected with a
275 CFTR knockdown vector expressing shRNA specific for CFTR, pLKO-CFTR
276 (shCFTR). Cells transfected with pLKO.1-puro Non-Target shRNA control vector
277 (shControl) were used as control and knockdown efficiency was confirmed by
278 western blotting (Figure 1D). CFTR knockdown increased intracellular bacterial
279 cellular numbers were assessed with a gentamicin protection assay (Figure 1E).
280 The results indicated that *C. jejuni* invasion was prevented by CFTR expression.
281 Another *C. jejuni* strain, 81-176, which was isolated from a patient during an
282 outbreak of *Campylobacter* enteritis (27) gave the same results as the NCTC
283 11168 strain (Supplementary Figure 2A and B). Therefore CFTR attenuated

284 invasion by another *C. jejuni* strain infection.

285

286 **CFTR attenuated microtubule-mediated *C. jejuni* invasion processes**

287 Since the number of intracellular bacterial cells in host cells can be influenced
288 at several steps, including adhesion, invasion, and survival, we next assessed
289 the relationship between CFTR and *C. jejuni* in the context of these processes.

290 In terms of *C. jejuni* cell numbers, adhesion and survival, there were no
291 differences between control cells and CFTR-expressing cells (Figure 2A and C).

292 In contrast, *C. jejuni* invasion was decreased by CFTR expression during the
293 early stage of infection (Figure 2B). Thus, we focused on *C. jejuni* invasion
294 pathways, which have two main parts: the endocytosis-like uptake pathway (26)
295 and the microtubule-dependent cellular transport pathway (28). Endocytosis-like
296 uptake pathways include those involving lipid rafts or clathrin-mediated
297 processes (29). Lipid raft domains are rich in cholesterol that promotes bacterial
298 adhesion and produces bacteria-containing vacuoles for cellular uptake (30).
299 Meanwhile, the scaffold protein clathrin binds to adaptor proteins to generate

300 clathrin-coated vesicles and promote endocytosis (31). M β -cd can affect lipid raft
301 components such as cholesterol to inhibit lipid raft-mediated endocytosis (32).
302 Chlorpromazine prevents clathrin formation at the cell membrane to decrease
303 clathrin-mediated endocytosis activity (33). Here, treatment of cells with either
304 m β -cd or chlorpromazine dramatically decreased the extent of *C. jejuni* invasion
305 in control cells. However, CFTR-mediated suppression of *C. jejuni* invasion was
306 sustained (Figure 3A and B). These data indicated that the effect of CFTR on *C.*
307 *jejuni* invasion was not related to the activity of endocytosis pathways.

308 Microtubules are dynamic structures that undergo polymerization and
309 depolymerization of tubulin to regulate both cell skeleton integrity and cellular
310 transport (34). After entry into host cells, *C. jejuni* invasion proceeds along
311 microtubules that act as intracellular tracks (28). Here, treatment with the
312 microtubule polymerization inhibitors nocodazole or colchicine (35,36)
313 suppressed *C. jejuni* invasion, but there was no difference in the number of
314 intracellular bacterial in control cells or cells CFTR-expressing cells (Figure 3C).
315 These data implied that CFTR negatively affected intracellular transport of *C.*

316 *jejuni* via the microtubule track, which in turn inhibited invasion.

317

318 **CFTR expression affect microtubule motor protein**

319 Microtubule polymerization promotes bacterial uptake and vacuole motility (37).

320 For *C. jejuni*, microtubules provide a means for invasion (28). To investigate the

321 participation of CFTR in microtubule-mediated *C. jejuni* invasion, we focused

322 microtubule tract and motor protein.

323 First, we investigated CFTR effect on microtubule transport tract. *C. jejuni*

324 infection did not change the amount of polymerized microtubules

325 (supplementary Figure 3A and B). The amount of polymerized microtubules was

326 estimated by western blot in CFTR-expressing cells (Figure 4A). But there were

327 no differences between HEK293 and HEK-wt-CFTR cells. And we confirmed

328 microtubules stability in CFTR-expressing cells by using the microtubule

329 depolymerization inhibitor, paclitaxel. Microtubule polymerization was increased

330 by paclitaxel treatment in CFTR-expressing cells (Figure 4B). Also, according th

331 the microtubule polymerization, the number of intracellular bacteria was

332 increased by paclitaxel treatment in HEK293 cells (Figure 4C). However, in
333 HEK-wt-CFTR cells, the intracellular bacterial number did not increase
334 significantly similar to HEK293 cells. These data indicated that CFTR did not
335 affect microtubule tract stability in microtubule-mediated transport.

336 Next, we checked that CFTR effect on microtubule motor protein, dynein. In the
337 previous study reported tht dynein inhibitor Na₃O₄ decreased *C. jejuni* invasion
338 via microtubule-mediated transport (38). Thus we used dynein inhibitor, Na₃VO₄,
339 on CFTR expressing cells, to stop the delivery in microtubule tract. According to
340 the Na₃VO₄ content, intracellular bacteria were decreased, and the differences
341 of bacterial number between HEK-wt-CFTR shControl and shCFTR cells were
342 abolished by Na₃VO₄ treatment (Figure 4D). Another strains, *C. jejuni* 81-176,
343 also result in similar to 11168 (supplementary Figure 4).

344 These results suggest that CFTR suppressed microtubule motor protein, which
345 functions interfere with microtubule mediated *C. jejuni* invasion.

346

347 **CFTR maturation is essential to inhibit *C. jejuni* invasion**

348 Cellular surface localization and appropriate folding are necessary for CFTR
349 channel activity (14,15). To examine how CFTR inhibited *C. jejuni* invasion, we
350 established cell lines that stably expressed two different CFTR mutants. The
351 G551D-CFTR mutant has a substitution of aspartic acid for glycine at amino acid
352 position 551. This mutant has appropriate folding trafficking to the cell surface
353 membrane, but does not have channel activity (39). Meanwhile, the
354 Δ F508-CFTR mutant has a single deletion of a phenylalanine residue at position
355 508. This mutant does not have appropriate glycosylation, folding, or trafficking
356 to the cell surface membrane (40). The expression of the mutant CFTR proteins
357 was confirmed by western blot (supplementary Figure 5A). Band C, indicative of
358 the mature complex-glycosylated form of CFTR, was detected for both wt-CFTR
359 and G551D-CFTR. Bands A and B indicate the non-glycosylated form and
360 immature core-glycosylated form, respectively, of CFTR (41). Band A and B
361 were both detected for cells expressing Δ F508-CFTR. The ion channel activity
362 as measured by efflux assay showed that active ion channels were detected
363 only for wt-CFTR cells (supplementary Figure 5B). Cells expressing the G551D

364 CFTR mutant, HEK-G551D-CFTR, had inhibition of *C. jejuni* invasion that was
365 similar to that of wt-CFTR cells (Figure 5A). G551D-CFTR knockdown also had
366 increases in intracellular bacterial cell numbers (Figure 5B and C). These results
367 indicated that suppression of *C. jejuni* invasion by CFTR expression was not
368 associated with CFTR ion channel activity. In contrast, expression of
369 Δ F508-CFTR did not suppress *C. jejuni* invasion (Figure 5A). A previous study
370 showed that defects in folding and trafficking of Δ F508-CFTR could be rescued
371 by treatment of cells with pharmacological folding correctors such as VX-809 at
372 low temperature conditions (27 °C) (42). Here we showed that treatment of cells
373 with VX-809 at low temperatures facilitated CFTR maturation and increased the
374 amount of band C, which indicates mature complex-glycosylated CFTR (Figure
375 5D). During CFTR maturation, *C. jejuni* invasion was suppressed by expressing
376 mature Δ F508-CFTR in the presence of VX-809 (Figure 5E). These results
377 suggest that CFTR expression, especially expression of mature and cell
378 surface-localized CFTR, was important for *C. jejuni* invasion.

379

380 **Endogenous CFTR attenuated *C. jejuni* invasion**

381 Next we confirmed CFTR-mediated suppression of *C. jejuni* invasion in
382 endogenously CFTR expressed T-84 cells. The shControl and shCFTR vector,
383 were transfected into T-84 cells by electroporation to assess whether
384 endogenous CFTR also inhibits *C. jejuni* invasion. We checked CFTR
385 knockdown efficiency by western blotting (Figure 6A). Similar to the
386 HEK-wt-CFTR experiment, intracellular bacterial number was increased by
387 endogenous CFTR knockdown in 3 hours *C. jejuni* infection (Figure 6B). Finally,
388 we checked endogenous CFTR expression level in *C. jejuni* infected T-84 cells.
389 In order to examine the mechanism how *C. jejuni* suppresses CFTR channel
390 activity in T-84 cells (Figure 1A). And we revealed that *C. jejuni* attenuated CFTR
391 gene expression and protein level in long term, 12 hours, infection (Figure 6C
392 and D). Taken together, these results suggest that, in intestinal cells, *C. jejuni*
393 suppressed CFTR to effectively into host cells.

394

395 **Discussion**

396 In this study, we investigated the role of CFTR in *C. jejuni* infection. We found
397 that overexpression of CFTR specifically inhibited invasion of *C. jejuni* (Figures 2
398 and 3) and that this inhibition appeared to depend on microtubules for transport
399 of *C. jejuni* vacuoles needed for bacterial invasion (Figures 4 and 5). *C. jejuni*
400 invasion was not suppressed in cells expressing an immature mutant CFTR that
401 is defective in glycosylation and trafficking, whereas cells expressing a CFTR
402 mutant that lacked ion channel activity had *C. jejuni* invasion that was similar to
403 that seen for HEK cells expressing wild type CFTR (Figure 6). Thus, we
404 conclude that CFTR glycosylation and localization to the cell surface might affect
405 bacterial interactions with cellular microtubules to suppress bacterial invasion.

406 The specific functions of intestinal epithelial cells, such as mucus production or
407 cellular polarization, might affect invasion processes of *C. jejuni*. Because we
408 focused on the relationship between CFTR and *C. jejuni* infection, we
409 overexpressed CFTR in HEK293 cells, a fibroblast line.

410 CFTR at the cell surface has several functional domains that have specific

411 structures, including two membrane-spanning domains, two nucleotide-binding
412 domains, and a regulatory region (14,15). The carboxyl terminal domain of
413 CFTR includes a PDZ domain that interacts with the cellular cytoskeleton by
414 binding scaffolding proteins such as NHERF1, N-WASP, EZRIN, and F-actin.
415 Localization of CFTR on the cell surface helps regulate clathrin and
416 N-WASP-mediated endocytosis pathways as well as Rab11 and
417 Rme-1-mediated recycling pathways. The Δ F508-CFTR mutant is thought to
418 have impaired interactions with NHERF1 and attenuated stabilization at the cell
419 surface (43). We considered that expression of wild type CFTR would result in
420 stable cell surface CFTR and increased interactions with scaffolding proteins
421 that in turn inhibit *C. jejuni* invasion. However, future studies should include
422 quantification of the amount of cell surface CFTR, which was examined only at a
423 qualitative level in this study.

424 During *C. jejuni*-invasion, microtubule tracts were associated with
425 CFTR-dependent inhibition of *C. jejuni* invasion (Figures. 4 and 5). Motor
426 proteins, such as members of the dynein and kinesin families, slide along

427 microtubules and are important for microtubule-mediated cellular transport (44).
428 Dynein and kinesin transports cargo toward the perinuclear region and from the
429 perinuclear region to the cell surface, respectively. CFTR trafficking is
430 maintained by microtubule-dependent transport involving dynein. Thus, CFTR
431 expression could regulate microtubule motor protein function, which might affect
432 delivery of *C. jejuni* vacuoles along microtubule tracts from the cell surface.
433 Further studies will also be needed to characterize the relationship between
434 CFTR and motor protein function.

435 Recently, other intestinal infection bacteria, including enteropathogenic
436 *Escherichia coli* (EPEC) and *Salmonella typhimurium* (*S. typhimurium*), were
437 reported to suppress CFTR ion channel activity (45,46). Moreover, in the
438 respiratory tract *P. aeruginosa* was shown to invade host cells via a
439 microtubule-dependent pathway that is regulated by CFTR (47). These findings
440 suggest that regulation of microtubule function by CFTR might be essential for
441 protection against invasive bacterial infection in a variety of tissues.

442

443 **Acknowledgments**

444 This work was supported by a Grant-in-Aid for Scientific Research from JSPS

445 KAKENHI (Grant Number JP 15K00819).

446 **References**

- 447 1. Parkhill J, Wren BW, Mungall K, Ketley JM, Churcher C, Basham D,
448 Chillingworth T, Davies RM, Feltwell T, Holroyd S, Jagels K, Karlyshev AV, Moule
449 S, Pallen MJ, Penn CW, Quail MA, Rajandream MA, Rutherford KM, van Vliet
450 AH, Whitehead S, Barrell BG. 2000. The genome sequence of the food-borne
451 pathogen *Campylobacter jejuni* reveals hypervariable sequences. *Nature*.
452 10;403(6770): 665-668
- 453 2. Szymanski CM, King M, Haardt M, Armstrong GD. 1995. *Campylobacter jejuni*
454 motility and invasion of Caco-2 cells. *Infect Immun*. 63(11): 4295-4300
- 455 3. Watson RO, Galán JE. 2008. *Campylobacter jejuni* survives within epithelial
456 cells by avoiding delivery to lysosomes. *PLoS Pathog*. 4(1):e14.doi:
457 10.1371/journal.ppat.0040014.
- 458 4. Golden NJ, Acheson DW. 2002. Identification of motility and autoagglutination
459 *Campylobacter jejuni* mutants by random transposon mutagenesis. *Infect*
460 *Immun*. 70(4), 1761-1771
- 461 5. Zheng J, Meng J, Zhao S, Singh R, Song W. 2008. *Campylobacter*-Induced
462 Interleukin-8 secretion in polarized human intestinal epithelial cells requires

463 Campylobacter-secreted cytolethal distending toxin- and Toll-Like
464 receptor-mediated activation of NF- κ B. Infect Immun. 76(10): 4498-4508

465 6. Nuijten PJ, van Asten FJ, Gaastra W, van der Zeijst BA. 1990. Structural and
466 functional analysis of two *Campylobacter jejuni* flagellin genes. J Biol Chem.
467 265:17798-17804

468 7. Konkel ME, Garvis SG, Tipton SL, Anderson DE Jr, Cieplak W Jr. 1997.
469 Identification and molecular cloning of a gene encoding a fibronectin-binding
470 protein (CadF) from *Campylobacter jejuni*. Mol Microbiol. 24(5):953-963

471 8. Flanagan RC, Neal-McKinney JM, Dhillon AS, Miller WG, Konkel ME. 2009.
472 Examination of *Campylobacter jejuni* putative adhesins leads to the identification
473 of a new protein, designated FlpA, required for chicken colonization. Infect
474 Immun. 77(6):2399-2407

475 9. Konkel ME, Larson CL, Flanagan RC. 2010. *Campylobacter jejuni* FlpA binds
476 Fibronectin and is required for maximal host cell adherence. J Bacteriol.
477 192(1):68-76

478 10. Deplancke B, Gaskins HR. 2001. Microbial modulation of innate defense:

479 goblet cells and the intestinal mucus layer. *Am J Clin Nutr.* 73(6):1132S-1141S

480 11. Bergstrom KS, Kissoon-Singh V, Gibson DL, Ma C, Montero M, Sham HP,
481 Ryz N, Huang T, Velcich A, Finlay BB, Chadee K, Vallance BA. 2010. Muc2
482 protects against lethal infectious colitis by disassociating pathogenic and
483 commensal bacteria from the colonic mucosa. *PLoS Pathog.* 13;6(5) :e1000902.
484 doi: 10.1371/journal.ppat.1000902.

485 12. McAuley JL, Linden SK, Png CW, King RM, Pennington HL, Gendler SJ,
486 Florin TH, Hill GR, Korolik V, McGuckin MA. 2007. MUC1 cell surface mucin is a
487 critical element of the mucosal barrier to infection. *J Clin Invest.* 117(8):
488 2313-2324

489 13. Thiagarajah JR, Verkman AS. 2013. Chloride channel-targeted therapy for
490 secretory diarrheas. *Curr Opin Pharmacol.* 13(6): 884-894

491 14. Stutts MJ, Canessa CM, Olsen JC, Hamrick M, Cohn JA, Rossier BC,
492 Boucher RC. 1995. CFTR as a cAMP-dependent regulator of sodium channels.
493 *Science.* 11;269(5225): 847-850

494 15. Riordan, JR. 2008. CFTR function and prospects for therapy. *Annu Rev*

495 Biochem. 77: 701-726

496 16. Norkina O, Burnett TG, De Lisle RC. 2004. Bacterial overgrowth in the cystic
497 fibrosis transmembrane conductance regulator null mouse small intestine. Infect
498 Immun. 72(10): 6040-6049

499 17. Field M, Graf LH Jr, Laird WJ, Smith PL. 1978. Heat-stable enterotoxin of
500 Escherichia coli: in vitro effects on guanylate cyclase activity, cyclic GMP
501 concentration, and ion transport in small intestine. Proc Natl Acad Sci U S A.
502 75(6):2800-2804

503 18. Lencer WI, Delp C, Neutra MR, Madara JL. 1992. Mechanism of cholera
504 toxin action on a polarized human intestinal epithelial cell line: role of vesicular
505 traffic. J Cell Biol. 117(6):1197-1209

506 19. Ma T, Thiagarajah JR, Yang H, Sonawane ND, Folli C, Galletta LJ, Verkman
507 AS. 2002. Thiazolidinone CFTR inhibitor identified by high-throughput screening
508 blocks cholera toxin-induced intestinal fluid secretion. J Clin Invest. 110(11):
509 1651-1658

510 20 Negoro S, Shimohata T, Hatayama S, Sato Y, Matsumoto M, Iba H, Aihara M,

511 Uebanso T, Hamada Y, Nishikawa Y, Yamasaki S, Mawatari K, Takahashi A.
512 (2014). *Campylobacter jejuni* infection suppressed Cl⁻ secretion induced by
513 CFTR activation in T-84 cells. J Infect Chemother. 20(11): 682-688

514 21. Pier GB, Grout M, Zaidi TS, Olsen JC, Johnson LG, Yankaskas JR,
515 Goldberg JB. (1996). Role of mutant CFTR in hypersusceptibility of cystic
516 fibrosis patients to lung infections. Science. 271(5245): 64-67

517 22. Gibson RL, Burns JL, Ramsey BW. 2003. Pathophysiology and management
518 of pulmonary infections in cystic fibrosis. Am J Respir Crit Care Med.
519 15;168(8):918-951

520 23. Cohen TS, Prince A. 2012. Cystic fibrosis: a mucosal immunodeficiency
521 syndrome. Nat Med. 5;18(4):509-19. doi: 10.1038/nm.2715.

522 24. DiMango E, Ratner AJ, Bryan R, Tabibi S, Prince A. 1998. Activation of
523 NF-kappaB by adherent *Pseudomonas aeruginosa* in normal and cystic fibrosis
524 respiratory epithelial cells. J Clin Invest. 1;101(11):2598-2605

525 25. MacEachran DP, Ye S, Bomberger JM, Hogan DA, Swiatecka-Urban A,
526 Stanton BA, O'Toole GA. 2007. The *Pseudomonas aeruginosa* secreted protein

527 PA2934 decreases apical membrane expression of the cystic fibrosis
528 transmembrane conductance regulator. *Infect Immun.* 75(8): 3902-12

529 26. Backert S, Boehm M, Wessler S, Tegtmeyer N. 2013. Transmigration route
530 of *Campylobacter jejuni* across polarized intestinal epithelial cells: paracellular,
531 transcellular or both? *Cell Commun Signal.* 30;11:72. doi:
532 10.1186/1478-811X-11-72.

533 27. Korlath JA, Osterholm MT, Judy LA, Forfang JC, Robinson RA. 1985. A
534 point-source outbreak of campylobacteriosis associated with consumption of raw
535 milk. *J Infect Dis.* 152(3):592-596

536 28. Oelschlaeger TA, Guerry P, Kopecko DJ. 1993. Unusual
537 microtubule-dependent endocytosis mechanisms triggered by *Campylobacter*
538 *jejuni* and *Citrobacter freundii*. *Proc Natl Acad Sci U S A.* 15;90(14): 6884-6888

539 29. Doherty GJ, McMahon HT. 2009. Mechanisms of endocytosis. *Annu Rev*
540 *Biochem.* 78:857-902

541 30. Zaas DW, Duncan M, Rae Wright J, Abraham SN. 2005. The role of lipid
542 rafts in the pathogenesis of bacterial infections. *Biochim Biophys Acta.*

543 30;1746(3): 305-313

544 31. Conner SD, Schmid SL. 2003. Regulated portals of entry into the cell. *Nature*.
545 6;422(6927):37-44

546 32. Rodal SK, Skretting G, Garred O, Vilhardt F, van Deurs B, Sandvig K. 1999.
547 Extraction of cholesterol with methyl-beta-cyclodextrin perturbs formation of
548 clathrin-coated endocytic vesicles. *Mol Biol Cell*. 10(4): 961-974.

549 33. Wang LH, Rothberg KG, Anderson RG. 1993. Mis-assembly of clathrin
550 lattices on endosomes reveals a regulatory switch for coated pit formation. *J Cell*
551 *Biol*. 123(5): 1107-1117

552 34. Apodaca G. 2001. Endocytic traffic in polarized epithelial cells: role of the
553 actin and microtubule cytoskeleton. *Traffic*. 2(3):149-159

554 35. Skoufias DA, Wilson L. 1992. Mechanism of inhibition of microtubule
555 polymerization by colchicine: inhibitory potencies of unliganded colchicine and
556 tubulin-colchicine complexes. *Biochemistry*. 28;31(3): 738-746

557 36. Vasquez RJ, Howell B, Yvon AM, Wadsworth P, Cassimeris L. 1997.
558 Nanomolar concentrations of nocodazole alter microtubule dynamic instability in

559 vivo and in vitro. Mol Biol Cell. 8(6): 973-985

560 37. Rothmeier E, Pfaffinger G, Hoffmann C, Harrison CF, Grabmayr H, Repnik U,
561 Hannemann M, Wölke S, Bausch A, Griffiths G, Müller-Taubenberger A, Itzen A,
562 Hilbi H. 2013. Activation of Ran GTPase by a *Legionella* effector promotes
563 microtubule polymerization, pathogen vacuole motility and infection. PLoS
564 Pathog. 9(9): e1003598

565 38. Hu L, Kopecko DJ.1999. *Campylobacter jejuni* 81-176 associates with
566 microtubules and dynein during invasion of human intestinal cells. Infect Immun.
567 67(8):4171-82.

568 39. Welsh MJ, Smith AE. 1993. Molecular mechanisms of CFTR chloride
569 channel dysfunction in cystic fibrosis. Cell. 2;73(7): 1251-1254

570 40. Kerem B, Rommens JM, Buchanan JA, Markiewicz D, Cox TK, Chakravarti
571 A, Buchwald M, Tsui LC. 1989. Identification of the cystic fibrosis gene: genetic
572 analysis. Science. 8;245(4922):1073-1080

573 41. Gregory RJ, Cheng SH, Rich DP, Marshall J, Paul S, Hehir K, Ostedgaard L,
574 Klinger KW, Welsh MJ, Smith AE. 1990. Expression and characterization of the

575 cystic fibrosis transmembrane conductance regulator. Nature.
576 27;347(6291):382-386

577 42. Okiyoneda T, Veit G, Dekkers JF, Bagdany M, Soya N, Xu H, Roldan A,
578 Verkman AS, Kurth M, Simon A, Hegedus T, Beekman JM, Lukacs GL. 2013.
579 Mechanism-based corrector combination restores Δ F508-CFTR folding and
580 function. Nat Chem Biol. 9(7): 444-454

581 43. Arora K, Moon C, Zhang W, Yarlagadda S, Penmatsa H, Ren A, Sinha C,
582 Naren AP. 2014. Stabilizing rescued surface-localized Δ F508 CFTR by
583 potentiation of its interaction with Na⁺/H⁺ exchanger regulatory factor 1.
584 Biochemistry. 53(25):4169-4179

585 44. Hirokawa N. 1998. Kinesin and dynein superfamily proteins and the
586 mechanism of organelle transport. Science. 281;279(5350):519-526

587 45. Marchelletta RR, Gareau MG, McCole DF, Okamoto S, Roel E, Klinkenberg
588 R, Guiney DG, Fierer J, Barrett KE. 2013. Altered expression and localization of
589 ion transporters contribute to diarrhea in mice with *Salmonella*-induced enteritis.
590 Gastroenterology. 145(6): 1358-1368

591 46. Ohland CL, DeVinney R, MacNaughton WK. 2012. *Escherichia coli*-induced
592 epithelial hyporesponsiveness to secretagogues is associated with altered
593 CFTR localization. *Cell Microbiol.* 14(4), 447-459

594 47. Sana TG, Baumann C, Merdes A, Soscia C, Rattei T, Hachani A, Jones C,
595 Bennett KL, Filloux A, Superti-Furga G, Voulhoux R, Bleves S 2015.
596 Internalization of *Pseudomonas aeruginosa* Strain PAO1 into Epithelial Cells Is
597 Promoted by Interaction of a T6SS Effector with the Microtubule Network. *MBio.*
598 2;6(3):e00712. doi: 10.1128/mBio.00712-15.

599

600 **Figure Legends**

601 **Figure 1. Changing of intracellular *C. jejuni* numbers in the presence of**

602 **CFTR expression** Cl⁻ efflux rates were estimated by 12 hours *C. jejuni* infected

603 cells in (A) T-84 cells and (B) HEK-wt-CFTR cells. After the stimulation, 125I⁻

604 was incorporated into cells for 6 minutes and the levels were assessed using a

605 gamma counter. (C) HEK293 cells and HEK-wt-CFTR cells were infected by *C.*

606 *jejuni* for 6 hours. The number of intracellular bacteria was estimated with a

607 gentamicin protection assay. (D) HEK-wt-CFTR cells were transfected with

608 pLKO-CFTR vector or pLKO.1-puro Non-Target shRNA control vector and the

609 protein expression of CFTR was detected by western blot. (E) HEK-wt-CFTR

610 shControl cells and HEK-wt-CFTR shCFTR cells were infected by *C. jejuni* for 6

611 hours and intracellular bacteria numbers were estimated with a gentamicin

612 protection assay. All data are means \pm SD of 3 independent experiment.

613 Statistical significance: **, p<0.01. NS.,No Significance. n=3-6.

614

615 **Figure 2. CFTR affects *C. jejuni* invasion during the early phase of infection**

616 **time, but does not affect bacterial adhesion and cellular survival.**

617 HEK-wt-CFTR cells were transfected with shControl or shCFTR vectors. The
618 cells were then infected by *C. jejuni* and (A) bacterial adhesion, (B) invasion
619 and (C) intracellular survival were assessed after 0, 1, 3 hours. All data are
620 means \pm SD of 3 independent experiment. Statistical significance: **, $p < 0.01$.
621 NS., No Significance. n=3-6.

622

623 **Figure 3. CFTR affected microtubule tracks in *C. jejuni* invasion.** HEK293
624 cells and HEK-wt-CFTR cells were treated with (A) methyl- β -cyclodextrin; m β -cd
625 (7.5 mM), (B) chlorpromazine (47 μ M), (C) nocodazole (33 μ M), or colchicine (10
626 μ M) for 1 hour, and infected by *C. jejuni* for 3 hours. In all experiments, the
627 number of intracellular bacteria was estimated using a gentamicin protection
628 assay. All data are means \pm SD of 3 independent experiment. Statistical
629 significance: **, $p < 0.01$., *, $p < 0.05$ NS. , No Significance. n=3-6.

630

631 **Figure 4. CFTR expression attenuated affect microtubule motor protein in**
632 ***C. jejuni* invasion.** (A) The polymerized tubulin content in HEK293 and

633 HEK-wt-CFTR cells were assessed by western blotting, treatment with paclitaxel
634 (5, 10 μ M) or DMSO for 1 hour. (B) The changing of microtubule
635 polymerization were quantified by measurement of polymerized α -tubulin and
636 normalized with respect to β -actin that was used as a loading control. (C)
637 HEK293 and HEK-wt-CFTR cells were treated with paclitaxel (5 or 10 μ M) or
638 DMSO for 1 hour prior to *C. jejuni* infection. And Intracellular bacterial numbers
639 were assessed by gentamicin protection assay. (D) HEK-wt-CFTR cells
640 shControl and shCFTR cells were treated by Na_3VO_4 (1 or 2 mM) for 1 hour prior
641 to *C. jejuni* infection. Intracellular bacterial numbers were assessed with
642 gentamicin protection assay. . All data are means \pm SD of 3 independent
643 experiment. Statistical significance: **, $p < 0.01$., *, $p < 0.05$ NS. , No Significance.
644 $n = 3-6$.

645

646 **Figure 5. Immature CFTR did not inhibit *C. jejuni* invasion.** (A) HEK293,
647 HEK-wt-CFTR, HEK-G551D-CFTR, or HEK- Δ F508-CFTR cells were infected
648 with *C. jejuni* for 0, 1, and 3 hours. Numbers of intracellular bacteria were

649 estimated using a gentamicin protection assay. (B) HEK-G551D cells were
650 transiently transfected with shControl or shCFTR, and CFTR levels were
651 detected by western blot. (C) HEK-G551D shControl and shCFTR cells were
652 infected with *C. jejuni* for 6 hours. Numbers of intracellular bacteria were
653 estimated with a gentamicin protection assay. (D) HEK- Δ F508-CFTR cells were
654 treated with VX-809 (40 μ M) or DMSO at 27 °C for 24 hr. CFTR expression was
655 detected by western blot. Bands A, B, and C indicate non-glycosylated,
656 immature core-glycosylated, and mature complex-glycosylated CFTR,
657 respectively. (E) HEK- Δ F508 and HEK-wt-CFTR cells were treated with VX-809
658 or DMSO at 27 °C for 24 hours and infected by *C. jejuni* for 3 hours. The
659 number of intracellular bacteria was estimated using a gentamicin protection
660 assay. All data are means \pm SD of 3 independent experiment. Statistical
661 significance: **, p<0.01., *, p<0.05., NS. , No Significance., n=3-6.

662

663 **Figure 6. Endogenous CFTR inhibited *C. jejuni* invasion in intestinal cells**

664 (A) CFTR knockdown level in, T-84 shControl and shCFTR cells, were detected

665 by western blotting. (B) The T-84, induced shControl and shCFTR plasmid, cells
666 were infected by *C. jejuni* 3 hours infection and estimated intracellular bacterial
667 number by gentamicin protection assay. During the 12 hours *C. jejuni*-infection,
668 CFTR (C) mRNA and (B) protein expression level were estimated in T-84 cells.
669 All data are means \pm SD of 3 independent experiment. Statistical significance: **,
670 $p < 0.01$., *, $p < 0.05$., NS. , No Significance. n=3-6.

Figure 1.




Figure 2.




Figure 3.




Figure 4.




Figure 5.




Figure 6.






FIG S1.




supplementary Figure 1. HEK-wt-CFTR cells stably and functionally express wt-CFTR. (A) HEK293 cells transfected with pcDNA-wt-CFTR vector stably expressed CFTR (HEK-wt-CFTR) as detected by western blot. (B) HEK293 cell and HEK-wt-CFTR cells were treated with forskolin or DMSO and CFTR channel activity was measured by assessing intracellular levels of ^{125}I - isotope incorporated into cells for 5 minutes prior to measurement with a gamma counter system. All data are means \pm SD of 3 independent experiment. Statistical significance: **, $p < 0.01$

FIG S2.




supplementary Figure 2. CFTR expression inhibited invasion by other *jejunii* strains (NCTC 11168 and 81-176). (A) HEK293 cells were infected by NCTC 11168 or 81-176 *C. jejuni* strains for 0, 3, 6, 9, or 12 hours. The number of intracellular bacteria were estimated using a gentamicin protection assay. (B) HEK293, HEK-wt-CFTR, HEK-wt-CFTR shControl and HEK-wt-CFTR shCFTR cells were infected by *C. jejuni* (81-176) for 6 hours. The numbers of intracellular bacteria were estimated with a gentamicin protection assay. All data are means \pm SD of 3 independent experiment. Statistical significance: *, $p < 0.05$

FIG S3.




supplementary Figure 3. *C. jejuni* infection did not affect tubulin polymerization. HEK293 cells and HEK-wt-CFTR cells were infected with *C. jejuni* for 3 hours. The level of polymerized tubulin was assessed with a western blot using an α -tubulin antibody and normalized relative to β -actin .

FIG S4.



supplementary Figure 4. CFTR expression inhibited microtubule-dependent invasion with other *jejuni* strains (81-176). (A) HEK293 cells and HEK-wt- CFTR cells were treated with nocodazole, colchicine, and Na₃VO₄ before 1 hour infection. The number of intracellular bacteria were estimated using a gentamicin protection assay. All data are means \pm SD of 3 independent experiment. Statistical significance: *, p<0.05. NS.,No Significance. n=6.

FIG S5.



supplementary Figure 5. Stable expression of mutant CFTR in transfected HEK293 cells. (A) HEK293 cells were transfected with pCDNA-G551D-CFTR and pCDNA-Δ-F508-CFTR. CFTR expression was detected by western blot and (B) CFTR channel activity was measured with an efflux assay.